Customers who struggle to afford the $1,000-plus list price for weight-loss drugs Zepbound and Wegovy can buy now and pay ...

Novo Nordisk, a Danish pharmaceutical company, has signed a major deal worth up to $2 billion for the rights to a new obesity ...

Right now, about 12% of American aged 18 or older (or 1 in 8 adults) are taking GLP-1 — glucagon-like peptide-1 — receptor ...

The once-daily pill combines Opko’s long-acting GLP-1/glucagon dual agonist peptide, dubbed OPK-88006, with Entera’s N-Tab ...

Spending growth for simple medications used to treat common health problems is outstripping spending growth for pricey ...

New research suggests that drugs like Ozempic may provide more health benefits than previously thought. These medications, ...

Patients with diabetes or obesity receiving GLP-1 RAs are unlikely to experience an increase in the already low rates of ...

The issuer is solely responsible for the content of this announcement.